Tzu-Fei Wang: Reassuring Real-World Data for Clinicians to Guide Anticoagulation in Prostate Cancer
Tzu-Fei Wang, Associate Professor at University of Ottawa, The Ottawa Hospital, and The Ottawa Hospital Research Institute, shared on LinkedIn about a recent article she and her colleagues co-authored, adding:
”Concerned about drug–drug interactions between DOACs and prostate cancer therapies?
New study of 2297 patients from Ontario and Alberta:
- No elevated risk for thrombosis with DOACs plus enzalutamide/ apalutamide
- No elevated risk for bleeding with DOAC plus abiraterone
Reassuring real-world data for clinicians to guide anticoagulation!”
Title: Risks of thrombosis and hemorrhage in concurrent use of anticoagulants and potential interacting prostate cancer agents
Authors: Tzu-Fei Wang, Anna Clarke, Mitchell Rath, Samantha Yoo, Deena Fremont, Cynthia Wu, Pietro Ravani, Dominick Bossé, Robert Talarico, Marc Carrier, Manish M. Sood
Read the Full Article on Cancer
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 16, 2026, 14:13Miguel Crato: Pleased to Share the Farewell Speech Closing My Chapter as President of the EHC
-
Jun 16, 2026, 14:09Abdul Mannan: Antiphospholipid Syndrome in Thrombotic Storm Mode
-
Jun 16, 2026, 14:06Harshal Kale: Connecting for Greater Impact at the Rotary International Conference
-
Jun 16, 2026, 14:04Tara Lech: Join the Movement Toward Better Anticoagulation Care
-
Jun 16, 2026, 13:56Christina (Tina) P.: Can Vitamin K Help Stabilize Your INR?
-
Jun 16, 2026, 13:49Tomáš Šimurda: Fibromics Team Secures EHA Innovation Grant for Innovative Research
-
Jun 16, 2026, 13:47Kaziwa Rasoul: Understanding Thrombosis in PNH
-
Jun 16, 2026, 13:46Fiona Robinson: New Ways to Engage Young People with Bleeding Disorders on the Upcoming NBDF Wednesday Webinar
-
Jun 16, 2026, 13:31Updated Recommendations for Pediatric Antithrombotic Therapies – JTH